Replies to post #684095 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

There were many more errors in the Chen Ling Reardon Chiocca Thanksgiving hit article timed to detract from NWBO’s then imminent MAA submission.

There was Reardon’s incorrect statement that idh status was not tracked.

There was Chiocca’s misstatement that 90% of placebos crossed over. (They thought they could get away with this, because in one, just one, of Dr.Liau’s dozens of interviews, she made this inadvertent misstatement, when everything else stated, published and peer reviewed was correct. It is no surprise that Exwannabe had the exact same childlike agenda on this.)

There was Chen’s error that mistated NWBO supposedly excluded all the patients with tumors that could escape treatment.

Etc.

There was also failure by the authors to correctly disclose their conflicts of interest.

The non-peer review is so error ridden it never should have seen the light of day, instead it was timed to slime DCVax-l ahead of NWBO’s MAA submission. This unfairly impacted not only any potential NWBO PPS momentum, but, more importantly, it was meant to put a false spotlight on DCVax-l at a time it was about to be reviewed by regulators.